Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fernandez

Showing results (591-600 of 645) with videos related to

Pageof 65
Sort By:
The Neurologist|September 2, 2011
DBS candidates that fall short on a levodopa challenge test: alternative and important indicationsTakashi Morishita, Maryam Rahman, Kelly D Foote, et al.
Neuroscience Letters|November 22, 2005
The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populationsSonja W Scholz, Georgia Xiromerisiou, Hon C Fung, et al.
Transplantation|October 27, 1996
An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometryR Garcia-Morales, V Esquenazi, K Zucker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 25, 2009
Brain penetration effects of microelectrodes and DBS leads in STN or GPiJ M Mann, K D Foote, C W Garvan, et al.
Archives of Neurology|May 10, 2006
Testosterone therapy in men with Parkinson disease: results of the TEST-PD StudyMichael S Okun, Hubert H Fernandez, Ramon L Rodriguez, et al.
Bone Marrow Transplantation|September 3, 2013
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remissionG Kunter, J B Perkins, J Pidala, et al.
Plos One|October 14, 2009
MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsisCatalin Vasilescu, Simona Rossi, Masayoshi Shimizu, et al.
The Lancet. Psychiatry|July 3, 2017
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trialKaren E Anderson, David Stamler, Mat D Davis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 16, 2021
Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment QuestionnaireGalit Kleiner, Hubert H Fernandez, Kelvin L Chou, et al.
JAMA Neurology|August 14, 2023
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical TrialRobert A Hauser, Alberto J Espay, Aaron L Ellenbogen, et al.
Pageof 65

Showing results (591-600 of 645) with videos related to

Sort By:
Pageof 65
The Neurologist|September 2, 2011
DBS candidates that fall short on a levodopa challenge test: alternative and important indicationsTakashi Morishita, Maryam Rahman, Kelly D Foote, et al.
Neuroscience Letters|November 22, 2005
The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populationsSonja W Scholz, Georgia Xiromerisiou, Hon C Fung, et al.
Transplantation|October 27, 1996
An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometryR Garcia-Morales, V Esquenazi, K Zucker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 25, 2009
Brain penetration effects of microelectrodes and DBS leads in STN or GPiJ M Mann, K D Foote, C W Garvan, et al.
Archives of Neurology|May 10, 2006
Testosterone therapy in men with Parkinson disease: results of the TEST-PD StudyMichael S Okun, Hubert H Fernandez, Ramon L Rodriguez, et al.
Bone Marrow Transplantation|September 3, 2013
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remissionG Kunter, J B Perkins, J Pidala, et al.
Plos One|October 14, 2009
MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsisCatalin Vasilescu, Simona Rossi, Masayoshi Shimizu, et al.
The Lancet. Psychiatry|July 3, 2017
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trialKaren E Anderson, David Stamler, Mat D Davis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 16, 2021
Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment QuestionnaireGalit Kleiner, Hubert H Fernandez, Kelvin L Chou, et al.
JAMA Neurology|August 14, 2023
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical TrialRobert A Hauser, Alberto J Espay, Aaron L Ellenbogen, et al.
Pageof 65